Earlier this week, Boston-based Delix Therapeutics announced the closing of its $70 million Series A financing. The company is seeking to parse out the apparent therapeutic benefits of psychedelics from their hallucinatory properties, dubbing such modified analogs ‘psychoplastogens.’ As the name suggests, Delix’s thesis – largely borne out of co-founder David Olson’s research – hinges on the…


Previous articlePTSF79 – Psychedelic Facilitator Abuse and Space Holding Ethics with Dr. Ido Cohen
Next articleLobe Sciences and the World Boxing Association Announce Initiative Targeting mTBI and PTSD